IRON | Disc Medicine, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	45.86 - 49.77
52 Week Range	27.79 - 68.73
Beta	0.88
Implied Volatility	76.09%
IV Rank	50.44%
Day's Volume	425,372
Average Volume	418,286
Shares Outstanding	34,632,900
Market Cap	1,711,557,918
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-08-12

Valuation
Profitability
Growth
Health
P/E Ratio	-12.48
Forward P/E Ratio	N/A
EPS	-3.96
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	82
Country	USA
Website	IRON

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

IRON's peers: ATXS, CNTA, FENC, OLMA, TRDA, ANEB, ADAG, ACRV, ANAB, MLYS, LRMR, OBIO, BMEA, GPCR, DICE, MORF, TERN, DAWN, ABOS, AMLX, MLTX, CRNX

*Chart delayed

Analyzing fundamentals for IRON we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see IRON Fundamentals page.

Watching at IRON technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on IRON Technicals page.